Response to Different Wheat Genotypes in Not-celiac Wheat Sensitivity
Non-celiac Wheat Sensitivity
About this trial
This is an interventional other trial for Non-celiac Wheat Sensitivity focused on measuring Non-celiac Wheat Sensitivity, ancient wheats, modern wheats, ATIs
Eligibility Criteria
Inclusion Criteria:
All the patients will meet the recently proposed criteria:
- negative serum anti-tissue transglutaminase and antiendomysium (EmA) immunoglobulin (Ig)A and IgG antibodies
- absence of intestinal villous atrophy
- IgE-mediated immunoallergic tests negative to wheat (skin prick tests and/or serum specific IgE detection)
- follow-up duration >12 months after the initial diagnosis
- at least two outpatient visits during the follow-up period.
Adjunctive criteria adopted in our patients will be:
- resolution of the gastrointestinal symptoms on a standard elimination diet, without wheat, cow's milk, egg, tomato, chocolate, or other food(s) causing self-reported symptoms
- symptom reappearance on DBPC wheat challenge, performed as described previously. As in previous studies, DBPC cow's milk protein challenge and other "open" food challenges will be also performed.
Exclusion Criteria:
Exclusion criteria will be:
- age <18 years
- positive EmA in the culture medium of the duodenal biopsies, even if the villi to crypts ratio in the duodenal mucosa was normal
- self-exclusion of wheat from the diet and refusal to reintroduce it before entering the study
- other organic gastrointestinal diseases (i.e. careful exclusion of Crohn's disease)
- concomitant treatment with steroids and/or antihistamines.
Sites / Locations
- Department of Internal Medicine, Giovanni Paolo II Hospital of SciaccaRecruiting
- Department of Internal Medicine, University Hospital of PalermoRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Active Comparator
Active Comparator
Placebo Comparator
Placebo Comparator
Active Comparator 1
Active Comparator 2
Placebo 1
Placebo 2
Wheat flour with high inflammatory response will be administered blindly versus placebo for 15 days in NCWS patients.
Wheat flour with low inflammatory response will be administered blindly versus placebo for 15 days in NCWS patients.
Placebo (xylose) will be administered blindly versus wheat flour with high inflammatory response for 15 days in NCWS patients.
Placebo (xylose) will be administered blindly versus wheat flour with low inflammatory response for 15 days in NCWS patients.